151 related articles for article (PubMed ID: 12192320)
21. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
22. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
23. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y
Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892
[TBL] [Abstract][Full Text] [Related]
24. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model.
Lumniczky K; Desaknai S; Mangel L; Szende B; Hamada H; Hidvegi EJ; Safrany G
Cancer Gene Ther; 2002 Jan; 9(1):44-52. PubMed ID: 11916244
[TBL] [Abstract][Full Text] [Related]
25. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
[TBL] [Abstract][Full Text] [Related]
27. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors.
Kutubuddin M; Federoff HJ; Challita-Eid PM; Halterman M; Day B; Atkinson M; Planelles V; Rosenblatt JD
Blood; 1999 Jan; 93(2):643-54. PubMed ID: 9885227
[TBL] [Abstract][Full Text] [Related]
28. Genetically engineered tumor cell vaccine in a head and neck cancer model.
Couch M; Saunders JK; O'Malley BW; Pardoll D; Jaffee E
Laryngoscope; 2003 Mar; 113(3):552-6. PubMed ID: 12616213
[TBL] [Abstract][Full Text] [Related]
29. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
30. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells.
Lakatosová-Andelová M; Jinoch P; Dusková M; Marinov I; Vonka V
Int J Oncol; 2008 Jan; 32(1):265-71. PubMed ID: 18097567
[TBL] [Abstract][Full Text] [Related]
31. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model.
Bonnekoh B; Greenhalgh DA; Chen SH; Block A; Rich SS; Krieg T; Woo SL; Roop DR
J Invest Dermatol; 1998 Jun; 110(6):867-71. PubMed ID: 9620291
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
35. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity.
Sakamoto C; Kohara H; Inoue H; Narusawa M; Ogawa Y; Hirose-Yotsuya L; Miyamoto S; Matsumura Y; Yamada K; Takahashi A; Tani K
Cancer Gene Ther; 2017 Apr; 24(4):165-174. PubMed ID: 28084317
[TBL] [Abstract][Full Text] [Related]
37. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
38. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens.
Hsieh CL; Pang VF; Chen DS; Hwang LH
Hum Gene Ther; 1997 Nov; 8(16):1843-54. PubMed ID: 9382951
[TBL] [Abstract][Full Text] [Related]
39. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production.
Tung C; Federoff HJ; Brownlee M; Karpoff H; Weigel T; Brennan MF; Fong Y
Hum Gene Ther; 1996 Dec; 7(18):2217-24. PubMed ID: 8953312
[TBL] [Abstract][Full Text] [Related]
40. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors.
Chang CJ; Tai KF; Roffler S; Hwang LH
J Immunol; 2004 Nov; 173(10):6025-32. PubMed ID: 15528337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
